Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3025–3048 of 8,385 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: serum sample Clear all

Conditions: Systemic Inflammatory Response Syndrome (SIRS), Sepsis, Severe Sepsis, Septic Shock
Interventions: Severe Sepsis Management Bundle; Other
Lead sponsor: University of Tennessee; Other
Eligibility: 1 Month to 18 Years
Enrollment: 30,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Multiple System Atrophy
Interventions: intravenous immunoglobulin (IVIg); Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Blood Cancer, Leukemia, Graft Versus Host Disease, Malignancy, CLL, NHL, Hodgkin's Disease, MDS
Interventions: non-myeloablative hematopoietic cell transplantation, Anti-Thymocyte Globulin, Cyclosporine, Mycophenolate Mofetil, G-CSF, Solumedrol, Acetaminophen, Diphenydramine, Hydrocortisone; Procedure · Drug
Lead sponsor: Stanford University; Other
Eligibility: 12 Months and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Prostate Cancer
Interventions: Oxaliplatin, Taxotere; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Male only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Metastatic Colorectal Cancer
Interventions: Bevacizumab, Oxaliplatin, Leucovorin, Fluorouracil, Cetuximab; Drug
Lead sponsor: US Oncology Research; Industry
Eligibility: 18 Years and older
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 82
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sedona, Arizona + 74 more

Conditions: Psoriasis
Interventions: Alefacept; Drug
Lead sponsor: Wake Forest University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Neoplasms, Breast
Interventions: lapatinib, paclitaxel, trastuzumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2019
U.S. locations: 14
States / cities: Roswell, Georgia • Joliet, Illinois • Detroit, Michigan + 10 more

Conditions: Polyneuropathies
Interventions: Rituximab; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 25 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Exudative Age-Related Macular Degeneration
Interventions: AL-78898A, Ranibizumab; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 50 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7
Interventions: Cyclophosphamide, IRX-2, Nivolumab, Surgery; Drug · Biological · Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Metastatic Renal Cell Carcinoma
Interventions: Evolocumab, Nivolumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Dallas, Texas • Houston, Texas

Conditions: Vitamin D Deficiency
Interventions: Vitamin D, 25(OH)D3; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Advanced Solid Tumors, Advanced B-cell NHL
Interventions: Urelumab, Nivolumab; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 11
States / cities: Palo Alto, California • Tampa, Florida • Chicago, Illinois + 6 more

Conditions: HER2-positive Breast Cancer, Metastatic Breast Cancer
Interventions: Pertuzumab, Trastuzumab, eribulin; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Germ Cell Tumors, Testis Cancer, Testicular Cancer, Embryonal Carcinoma, Nonseminomatous Germ Cell Tumor
Interventions: Brentuximab Vedotin; Drug
Lead sponsor: Nabil Adra; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 4
States / cities: Los Angeles, California • Indianapolis, Indiana • New York, New York

Conditions: Breast Cancer
Interventions: Capecitabine, Bevacizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 57
States / cities: Birmingham, Alabama • Burbank, California • Glendale, California + 39 more

Conditions: NSCLC, Melanoma
Interventions: BA3071, Nivolumab, Pembrolizumab, Pemetrexed (Alimta); Biological · Drug
Lead sponsor: BioAtla, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 9
States / cities: Los Angeles, California • Atlanta, Georgia • Dyer, Indiana + 5 more

Conditions: Newly Diagnosed Oligometastatic Prostate Cancer
Interventions: radical prostatectomy, stereotactic body radiotherapy, Leuprolide, apalutamide, abiraterone; Procedure · Radiation · Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 3
States / cities: Long Beach, California • West Los Angeles, California • Richmond, Virginia

Conditions: Juvenile Psoriatic Arthritis, Psoriasis, Arthritis, Juvenile
Interventions: Ustekinumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 10
States / cities: Huntington Beach, California • Los Angeles, California • Chicago, Illinois + 6 more

Conditions: Plaque Psoriasis
Interventions: Deucravacitinib, Ustekinumab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 40 Years and older
Enrollment: 3,040 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 122
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 101 more

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
Interventions: Paclitaxel, Carboplatin, Atezolizumab, Bevacizumab, Atezolizumab Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 127
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 101 more

Conditions: Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: cetuximab, paclitaxel, bevacizumab; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions: FATE-NK100, Interleukin-2; Biological · Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Diffuse Large B-cell Lymphoma
Interventions: Loncastuximab Tesirine, Rituximab; Drug
Lead sponsor: ADC Therapeutics S.A.; Industry
Eligibility: 65 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 29
States / cities: Tucson, Arizona • Little Rock, Arkansas • Aurora, Colorado + 24 more

Search by objective public record fields.

Electronic Application of a Severe Sepsis Screening Tool and Management Bundle

Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins

Allogeneic Transplantation From Related Haploidentical Donors

Study of Oxaliplatin and Taxotere in Prostate Cancer

Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer

Long-Term One Year Use of Alefacept (Amevive®) in Moderate to Severe Chronic Plaque Type Psoriasis

ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib

Rituximab to Treat Neuropathy With Anti-MAG Antibodies

Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration

Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer

A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)

Effects of Vitamin D3 Versus 25OHD3 on Mineral Metabolism and Immune Function

An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma

Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer

Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors

A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer

A Phase 1/2 Study of BA3071 in Patients With Solid Tumors

Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer

A Study of Ustekinumab in Pediatric Participants (U-POPS) With Juvenile Psoriatic Arthritis or Psoriasis

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer

Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int

A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)